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in the tube graft configuration, whereas in the bifurcated
endograft, each iliac attachment system was composed of
a self-expanding cylindrical frame with three metal endo-
hooks. All of these metal components are composed of
Elgiloy, an alloy of cobalt, chromium, and nickel that pro-
vides a combination of high strength, high performance,
as well as fatigue and corrosion resistance.3 Nevertheless,
close analysis of the initial hook design revealed an approx-
imately 90-degree angle that likely subjected a discrete
segment of the hook to maximal stress and introduced a
potential site for microcrack formation. Therefore, the
hooks were redesigned with a larger radius of curvature
that increased stress distribution along a larger hook seg-
ment, reducing the magnitude of the maximal stress and
sites at risk for microcrack formation (Fig 1). In vitro test-
ing performed by the manufacturer suggests that the
attachment system can withstand at least 15 years of in
vivo cyclic loading.4 After the device was reengineered, the
clinical trial was resumed in November 1995.
Completion of the trial and analysis of 1-year implant
data led to FDA approval of the redesigned Ancure endo-
graft (Guidant, Inc) in September 1999.2 Overall,
midterm clinical results continue to be promising with
approximately 75% of patients demonstrating a reduction
in aneurysm diameter of at least 5 mm 3 years after graft
implantation.5 Nevertheless, the number of carefully ana-
lyzed patients who have been followed for a substantial
time period after implantation remains relatively small.
Fundamentally, the long-term durability of this device
and, for that matter, all other available endografts remains
unknown. Indeed, metal component fractures in AneuRx
and Vanguard endografts have been observed.6-8
In 1993, EndoVascular Technologies, Inc, initiated a
clinical trial sponsored by the Food and Drug
Administration (FDA) of the EndoVascular Grafting
System (EGS) for the treatment of abdominal aortic
aneurysm.1 Fixation of the endograft to the host aorta was
dependent on a series of hooks located at proximal and
distal extents of the graft. In the initial phase of this trial
endovascular repair was successfully completed in 39
patients. However, explantation of a device, due to a per-
sistent endoleak with aneurysm enlargement 12 months
after implantation, revealed single-hook fractures of both
proximal and distal attachment systems.2 This observation
prompted a review of all the plain abdominal radiographs,
which identified eight additional patients with fractured
attachment systems. As a consequence, additional patient
enrollment in the trial was discontinued in January 1995.
In order to reduce the maximum force on any given
hook, the EGS superior attachment system had been ini-
tially designed as a self-expanding cylindrical frame con-
sisting of four sets of V-hooks for a total of eight hooks.
The superior and inferior attachment systems are identical
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Two cases of delayed (36-month) Ancure hook fracture are reported in patients who experienced a decrease in aneurysm
size and no evidence of endoleak. Both devices used redesigned hooks and are otherwise identical to those devices cur-
rently used in clinical practice. Notably, hook fractures were not visualized on all abdominal radiographic views, nor were
they noted on the final “institutional” report by the reviewing radiologist. Careful clinical follow-up with multiple-view
abdominal radiographs remains essential for all patients treated with an endovascular graft, with particular attention
directed to the integrity of the metal components. The broader clinical significance of this observation with respect to
the Ancure endograft remains to be defined. (J Vasc Surg 2001;34:353-6.)
Therefore, close scrutiny of device durability by all
implanting clinicians is mandatory to determine the inci-
dence and clinical significance of component failure. We
report herein the observation in two patients of isolated
hook fractures 36 months after implantation of Ancure
bifurcated endografts. Both devices used redesigned hooks
and are otherwise identical to those devices currently used
in clinical practice.
CASE REPORT
Patient 1. A 67-year-old man with an infrarenal abdominal
aortic aneurysm underwent successful exclusion with the Ancure
device. The maximum aneurysm diameter was 59 mm with supe-
rior neck diameter and length of 21.9 mm and 36 mm, respectively.
The aneurysm was treated with a 24-mm × 16-cm bifurcated
Ancure graft. Follow-up computed tomography (CT) scans and
abdominal x-ray films at 1-, 3-, 6-, 12-, and 24-month post-implant
time points demonstrated relatively little change in aneurysm size,
no evidence of endoleak, and an intact endograft. Abdominal CT
scan and four-view abdominal x-ray films obtained 36 months after
graft implantation showed a reduction of aneurysm diameter (54
mm), increased angulation, and the presence of a single endo-hook
fracture of the superior attachment system (Fig 2). Neither
endoleak nor device migration has been observed.
Patient 2. A 77-year-old man with an infrarenal abdominal
aortic aneurysm underwent successful exclusion with the Ancure
device. The maximum aneurysm diameter was 55 mm with supe-
rior neck diameter and length of 23.5 mm and 21 mm, respec-
tively. The aneurysm was treated with a 24-mm × 16-cm
bifurcated Ancure graft. Approximately 7 months after graft
implantation, the patient received bilateral renal artery stents.
Follow-up CT scans and abdominal x-ray films at 3-, 6-, 12-, and
24-month post-implant time points demonstrated little change in
aneurysm size, no evidence of endoleak, and an intact endograft.
Abdominal CT scan and four-view abdominal x-ray films obtained
36 months after graft implantation showed a reduction of
aneurysm size of more than 5 mm and the presence of a single
endo-hook fracture of the superior attachment system. Neither
endoleak nor device migration has been observed.
DISCUSSION
Metal components are critical constituents of all aortic
endografts, serving a number of device-specific functions,
including fixation of the endograft to the host aorta and
provision of an adequate seal at the proximal and distal
extents of the device. Among certain classes of devices,
appropriate coupling of modular components and mainte-
nance of lumen patency are also dependent on metal com-
ponents. In this regard, bench models for accelerated
fatigue testing are important preclinical tools for assessing
acute component integrity and for providing an initial pre-
diction of long-term endograft durability. In vitro models,
however, are based on the assumption that both in vivo
forces and the biological microenvironment are accurately
approximated in the test system. In large measure, how-
ever, these factors remain incompletely defined for aortic
endografts. Furthermore, limited clinical data exist regard-
ing the long-term durability of endografts that is required
for the validation of any predictive experimental system.
Indeed, the development of accurate in vitro models for
the assessment of heart valve substitutes evolved over a
period of several decades through a combination of exper-
imental, computational, and clinical investigation.9
The ultimate performance of any attachment system
hinges on material composition, system design, and other
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Fig 1. Schematic representation of forces exerted on endo-
hooks: current (A) and initial (B) hook designs. Arrows represent
qualitative estimate of force magnitude and direction. 
Fig 2. Abdominal x-ray films demonstrating aneurysm sac
changes and a hook fracture detected 36 months after endograft
implantation. Arrow illustrates hook fracture.
A B
factors that influence the magnitude and distribution of
the applied stress field, including the position of the device
relative to the axis of blood flow and the host aortic wall.
Elgiloy is a metal alloy that is a common component of a
variety of endovascular devices, including the Ancure
endograft. On the basis of conventional mechanical test-
ing, Elgiloy has a high-yield strength and elastic modulus
and is corrosion and fatigue resistant.3 However, it is note-
worthy that published material properties usually have
been derived from fatigue studies of relatively large sam-
ples. For example, constant amplitude axial fatigue testing
often involves the use of metal components with diameters
ranging from 5 to 25 mm, and the measurement of fatigue
crack growth rates has often relied on the testing of spec-
imen bars with widths of 10 to 100 mm.10 It is significant
that the extrapolation of data obtained from large speci-
mens to predict the behavior and mechanical properties of
smaller components may yield invalid projections, a phe-
nomenon that has been termed a size effect.11 Thus, life
cycle data for a given material will be accurate only when
assessed in a clinically relevant configuration. This is par-
ticularly important for fine wires, which, as a consequence
of material processing, may have fine grain microstruc-
tures oriented along the axis of wire that can lead to sig-
nificant anisotropy in fatigue properties.
In an investigation of the durability of Elgiloy wire,
Schmidt et al10 defined a fatigue life curve for 0.78-mm
diameter wire in air. Given an applied load of 22.2 N and
a maximum stress at the wire apex of approximately 1500
MPa, failure was noted after 1 × 107 cycles. Studies at
lower levels of applied force were not conducted. In this
report, upper hooks with a wire diameter of approximately
0.4 mm fractured after 36 months (approximately 108
cycles). Thus, an appropriate estimation of the in vivo
stress level that may have been associated with hook fail-
ure is not possible. Nevertheless, the in vivo forces that
lead to hook failure were undoubtedly considerably lower
than 20 N per hook. Current estimates of the physiologic
loading forces on the juxtarenal segment of aortic endo-
grafts are limited with most experimental studies directed
at defining the longitudinal forces required to cause endo-
graft migration.12,13 However, Morris et al14 have recently
developed a series of theoretical estimates of the resultant
forces on the proximal portion of bifurcated endografts, as
related to device diameter and iliac leg angle. For a 24-mm
× 16-cm bifurcated endograft, a total force of 12 to 15 N
was estimated or, in the case of an eight-hook attachment
system, approximately 1.5 to 1.9 N per hook. This esti-
mate, however, may be limited because the model did not
account for neck or endograft angulation. Regardless, as
an initial calculation, this work and the prior study by
Schmidt et al10 suggest that in vivo forces may be of suffi-
cient magnitude to induce hook failure over the long-term
life of the implant. Moreover, additional mechanical and
chemical processes in vivo may play a significant role in
microcrack initiation and propagation.9 Further experi-
mental and computational analysis will be essential to
accurately define the physiologic stress profile on these
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devices and the associated fatigue life curve at relevant
force levels for this and other material compositions.
It is noteworthy that the hook fractures noted in this
report were not visualized on all abdominal radiographic
views, nor were these fractures noted on the final “institu-
tional” report by the reviewing radiologist. Thus, it is essen-
tial that abdominal radiographs include anteroposterior,
lateral, and oblique images and that these studies be directly
reviewed by the clinician responsible for patient follow-up.
Approximately 8000 Ancure devices have been
implanted in the United States since FDA approval was
given in September 1999. However, as of February 2001,
only 167 Ancure endografts had been followed under an
FDA clinical trial protocol with implant periods approach-
ing or exceeding 36 months (Don Schwarten, Guidant
Corporation, oral communication, February 2001). To
date, isolated hook fractures have been detected in two
(1.2%) of these 167 devices. In both cases, clinical seque-
lae have not been noted. However, a risk for additional
hook fractures, endoleak, or device migration is present,
and careful follow-up is mandatory.
CONCLUSIONS
Two cases of delayed (36-month) Ancure hook frac-
ture are reported in patients who experienced a decrease in
aneurysm size and no evidence of endoleak. Nevertheless,
these events raise a risk for later endoleak or graft migra-
tion. Although initial in vitro bench models have provided
reassuring estimates for device durability, these experimen-
tal systems have not been validated. Thus, patient moni-
toring and frequent examinations with CT or ultrasound
scanning, along with multiple-view abdominal radiographs,
remain essential. Particular attention should be directed to
the integrity of the proximal and distal attachment sites.
Further follow-up will be required to determine if the
redesigned Ancure attachment system has substantially
eliminated the risk of hook failure noted in the initial endo-
graft design or simply shifted the fatigue to failure curve to
a later, though clinically relevant, time point.
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